SJP Biotec GmbH

SJP Biotec GmbH is a clinical-stage precision oncology company pioneering a first-in-class Selective Translation Regulatory Inhibitor (STRI) platform aimed at overcoming treatment resistance in refractory cancers. The company focuses on RAS-driven, hormone-receptor-positive, and immune-refractory tumors, developing a novel pipeline of small molecules ready for regulatory-grade trials. Backed by a Scientific Advisory Board of leading authorities in RAS and breast cancer biology, SJP has established partnerships with prominent medical centers worldwide.